Rogue stem cell clinics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32009438.
- Also identified by DOI 10.1302/0301-620X.102B2.BJJ-2019-1104.R1 and PMC identifier 7002842.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cell therapies hold significant promise for the treatment of injured or diseased musculoskeletal tissues. However, despite advances in research, there is growing concern about the increasing number of clinical centres around the world that are making unwarranted claims or are performing risky biological procedures. Such providers have been known to recommend, prescribe, or deliver so called 'stem cell' preparations without sufficient data to support their true content and efficacy. In this annotation, we outline the current environment of stem cell-based treatments and the strategies of marketing directly to consumers. We also outline the difficulties in the regulation of these clinics and make recommendations for best practice and the identification and reporting of illegitimate providers. Cite this article: <i>Bone Joint J</i> 2020;102-B(2):148-154.
Medical subject headings
- Ambulatory Care Facilities
- Direct-to-Consumer Advertising
- Marketing of Health Services
- Musculoskeletal Diseases
- Patient Safety
- Stem Cell Transplantation